Scribe is a clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines for cardiovascular and metabolic diseases. Scribe uses its proprietary CRISPR by Design platform to engineer CasX enzymes, which are smaller than standard Cas9 enzymes and offer distinct intellectual property positioning. The company’s technology includes ELXR, a gene-silencing tool that represses gene expression without permanently altering DNA, and XE, a gene-editing tool for permanent modifications. Scribe's lead program, STX-1150, is in Phase 1 clinical trials and targets elevated LDL-C by silencing the PCSK9 gene in the liver. Its preclinical pipeline includes STX-1200 for elevated lipoprotein(a) and STX-1400 for severely elevated triglycerides. All three internal programs utilize lipid nanoparticle delivery to target hepatocytes. Scribe's business model combines the development of its own cardiovascular pipeline with strategic collaborations. The company sells access to its CRISPR platform to pharmaceutical partners, including Sanofi and Lilly, for applications in genetic, neurological, and neuromuscular disorders. These partnerships provide research funding and milestone payments to support Scribe’s proprietary programs. Scribe argues that its engineered CRISPR systems overcome the activity and delivery limitations of first-generation approaches, enabling durable treatments for large patient populations.